AC Immune (NASDAQ:ACIU) Receives Buy Rating from HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $16.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 350.70% from the stock’s current price.

Separately, StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st.

AC Immune Price Performance

Shares of ACIU opened at $3.55 on Friday. AC Immune has a 1 year low of $2.25 and a 1 year high of $5.14. The stock has a 50 day simple moving average of $3.27 and a 200-day simple moving average of $3.47.

Hedge Funds Weigh In On AC Immune

Several institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC acquired a new stake in shares of AC Immune in the first quarter valued at $30,000. BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after acquiring an additional 8,423 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new position in shares of AC Immune during the second quarter worth approximately $40,000. Vanguard Capital Wealth Advisors bought a new stake in shares of AC Immune during the second quarter valued at approximately $56,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after purchasing an additional 7,400 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.